BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells.

ABSTRACT: Melanoma is the most dangerous form of skin cancer with a growing incidence over the last decades. Fourty percent of all melanomas harbor a mutation in the signaling adaptor BRAF (V600E) that results in ERK hyperactivity as an oncogenic driver. In these cases, treatment with the BRAF^V600E inhibitors Vemurafenib (VEM) or Dabrafenib (DAB) coapplied with the MEK1/2 inhibitors Cobimetinib (COB) or Trametinib (TRA) can result in long-term suppression of tumor growth. Besides direct suppression of ERK activity, these inhibitors have been reported to also modulate tumor immune responses, and exert pro-inflammatory side effects such as fever and rash in some patients. Here we asked for potential effects of BRAF^V600E inhibitors on dendritic cells (DC) which are essential for t

SUBMITTER: Hajek E 

PROVIDER: S-EPMC6033361 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature